Developers are razing most of the 40 buildings in the complex, prepping for a sale of the campus either as one parcel or building-by-remaining-building.
Authorities in Europe have added two Roche cancer drugs to their list of stolen meds that wholesalers and healthcare providers should be on the lookout for. That brings the tally to 5 drugs that the European Medicines Agency says should be closely examined for signs of tampering.
Roche's Ventana Medical Systems is linking up with Arizona State University to launch a diagnostics-focused master's degree professional program at the school.
Italian finance police searched the offices of the Italian Medicines Agency, looking for evidence in a criminal probe of potential fraud and market manipulation by the Swiss drugmakers Novartis and Roche. Officials have been investigating allegations that the two companies colluded to boost sales of Lucentis, their eye drug, by sidelining off-label use of the drug's close cousin, Avastin.
Roche's Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer.
Doctors have long repurposed Roche's Avastin for the eye in place of using the company's pricier Lucentis to save money. Now, a study says the U.S. could save almost $3 billion a year if Medicare patients received the cheaper drug--a prospect Roche isn't so keen on.
After failing to buy Illumina in 2012 and deciding to close its 454 Life Sciences sequencing unit last year, Roche has been looking for technologies to strengthen its diagnostic business.
Today, Roche put out the word that their PD-L1 drug MPDL3280A won the FDA's coveted breakthrough therapy designation, potentially putting it on an inside track at the agency, which has been hurrying along new medicines in the pipeline.
Three months ago, antitrust authorities in Italy fined Novartis and Roche $251 million on charges they colluded to protect sales of their eye drug, Lucentis. Now, that country's Health Ministry is seeking further damages.
Execs with Roche's diagnostics arm remain bullish about U.S. growth prospects even as reimbursement cuts place new pressures on the sector overall. An executive with the company anticipates booming demand to the point that price reductions aren't on the table.